DMRA•Damora Therapeutics’ third-quarter 2026 net loss widened to $31.99 million. Cash, cash equivalents and marketable securities totaled $528.5 million at September 30, which the company expects to fund operations into the second half of 2029.
Damora Therapeutics’ third-quarter 2026 net loss widened to $32 million from a year earlier. Research and development expenses rose to $25.5 million, and general and administrative expenses increased to $11.4 million. The company had $528.5 million in cash, cash equivalents and marketable securities at September 30, expected to fund operations into the second half of 2029. FDA clearance enabled U.S. initiation of the CLARITY-101 trial, and two clinical proof-of-concept datasets are expected beginning mid-2027.
